Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1967 1
1968 1
1970 1
1986 1
1987 1
1988 2
1989 1
1990 4
1991 2
1993 1
1994 1
1995 2
1997 2
1998 1
1999 1
2000 1
2003 1
2006 2
2007 1
2009 1
2010 2
2012 3
2013 1
2014 2
2015 2
2016 2
2017 4
2018 2
2019 1
2020 2
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Alpha emitter radium-223 and survival in metastatic prostate cancer.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators. Parker C, et al. N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755. N Engl J Med. 2013. PMID: 23863050 Free article. Clinical Trial.
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, Lambert B, Delrue L, Bultijnck R, Claeys T, Goetghebeur E, Villeirs G, De Man K, Ameye F, Billiet I, Joniau S, Vanhaverbeke F, De Meerleer G. Ost P, et al. Among authors: billiet i. J Clin Oncol. 2018 Feb 10;36(5):446-453. doi: 10.1200/JCO.2017.75.4853. Epub 2017 Dec 14. J Clin Oncol. 2018. PMID: 29240541 Clinical Trial.
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, Dumez H, de Santis M, Théodore C, Leahy MG, Chester JD, Verbaeys A, Daugaard G, Wood L, Witjes JA, de Wit R, Geoffrois L, Sengelov L, Thalmann G, Charpentier D, Rolland F, Mignot L, Sundar S, Symonds P, Graham J, Joly F, Marreaud S, Collette L, Sylvester R; European Organisation for Research and Treatment of Cancer Genito-Urinary Cancers Group; Groupe d'Etude des Tumeurs Urogénitales; National Cancer Research Institute Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; German Association of Urologic Oncology. Sternberg CN, et al. Lancet Oncol. 2015 Jan;16(1):76-86. doi: 10.1016/S1470-2045(14)71160-X. Epub 2014 Dec 11. Lancet Oncol. 2015. PMID: 25498218 Free article. Clinical Trial.
Introducing new technology safely into urological practice.
Van Bruwaene S, Namdarian B, Challacombe B, Eddy B, Billiet I. Van Bruwaene S, et al. Among authors: billiet i. World J Urol. 2018 Apr;36(4):543-548. doi: 10.1007/s00345-018-2173-2. Epub 2018 Jan 11. World J Urol. 2018. PMID: 29327248 Review.
MR imaging of the pelvic floor.
Seynaeve R, Billiet I, Vossaert P, Verleyen P, Steegmans A. Seynaeve R, et al. Among authors: billiet i. JBR-BTR. 2006 Jul-Aug;89(4):182-9. JBR-BTR. 2006. PMID: 16999318 Review.
Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study).
Buelens S, Poelaert F, Claeys T, De Bleser E, Dhondt B, Verla W, Ost P, Rappe B, De Troyer B, Verbaeys C, Kimpe B, Billiet I, Plancke H, Fransis K, Willemen P, Ameye F, Decaestecker K, Lumen N. Buelens S, et al. Among authors: billiet i. BJU Int. 2022 Jun;129(6):699-707. doi: 10.1111/bju.15553. Epub 2021 Aug 8. BJU Int. 2022. PMID: 34289231
Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.
Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S. Grimm P, et al. Among authors: billiet i. BJU Int. 2012 Feb;109 Suppl 1:22-9. doi: 10.1111/j.1464-410X.2011.10827.x. BJU Int. 2012. PMID: 22239226 Review.
Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy.
De Bruycker A, Lambert B, Claeys T, Delrue L, Mbah C, De Meerleer G, Villeirs G, De Vos F, De Man K, Decaestecker K, Fonteyne V, Lumen N, Ameye F, Billiet I, Joniau S, Vanhaverbeke F, Duthoy W, Ost P. De Bruycker A, et al. Among authors: billiet i. BJU Int. 2017 Dec;120(6):815-821. doi: 10.1111/bju.13938. Epub 2017 Jul 16. BJU Int. 2017. PMID: 28646594
46 results